{"title":"吸烟/戒烟和代谢综合征","authors":"G. Kolovou, V. Kolovou, S. Mavrogeni","doi":"10.1080/17584299.2016.1228285","DOIUrl":null,"url":null,"abstract":"Abstract The metabolic syndrome (MetS) is a common cluster of pre-morbid, modified metabolic–vascular risk factors/diseases (visceral obesity, hyperglycaemia, dyslipidaemia and hypertension) associated with increased cardiovascular (CV) morbidity, fatty liver and risk of cancer. Several studies reported a higher incidence of MetS in smokers. Cigarette smoking plays a substantial role in the pathogenesis of numerous chronic diseases such as CV disease (CVD), cancer, lung disease and others. However, due to the existence of the so-called “smoking paradox”, the impact of this risk factor on CVD mortality is still not clear. Smoking cigarettes may increase risk of MetS or worsen it by numerous mechanisms. Furthermore, individuals who quit smoking tend to increase their body weight. The possibility of gaining weight can stop smokers from quitting and increases the risk of relapse, particularly in women. Herein, we review the cigarette smoking status (active/cessation) in relation to the MetS.","PeriodicalId":55252,"journal":{"name":"Clinical Lipidology","volume":"51 1","pages":"14 - 6"},"PeriodicalIF":0.0000,"publicationDate":"2016-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"24","resultStr":"{\"title\":\"Cigarette smoking/cessation and metabolic syndrome\",\"authors\":\"G. Kolovou, V. Kolovou, S. Mavrogeni\",\"doi\":\"10.1080/17584299.2016.1228285\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Abstract The metabolic syndrome (MetS) is a common cluster of pre-morbid, modified metabolic–vascular risk factors/diseases (visceral obesity, hyperglycaemia, dyslipidaemia and hypertension) associated with increased cardiovascular (CV) morbidity, fatty liver and risk of cancer. Several studies reported a higher incidence of MetS in smokers. Cigarette smoking plays a substantial role in the pathogenesis of numerous chronic diseases such as CV disease (CVD), cancer, lung disease and others. However, due to the existence of the so-called “smoking paradox”, the impact of this risk factor on CVD mortality is still not clear. Smoking cigarettes may increase risk of MetS or worsen it by numerous mechanisms. Furthermore, individuals who quit smoking tend to increase their body weight. The possibility of gaining weight can stop smokers from quitting and increases the risk of relapse, particularly in women. Herein, we review the cigarette smoking status (active/cessation) in relation to the MetS.\",\"PeriodicalId\":55252,\"journal\":{\"name\":\"Clinical Lipidology\",\"volume\":\"51 1\",\"pages\":\"14 - 6\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2016-09-12\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"24\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lipidology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/17584299.2016.1228285\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lipidology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/17584299.2016.1228285","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q","JCRName":"Medicine","Score":null,"Total":0}
Cigarette smoking/cessation and metabolic syndrome
Abstract The metabolic syndrome (MetS) is a common cluster of pre-morbid, modified metabolic–vascular risk factors/diseases (visceral obesity, hyperglycaemia, dyslipidaemia and hypertension) associated with increased cardiovascular (CV) morbidity, fatty liver and risk of cancer. Several studies reported a higher incidence of MetS in smokers. Cigarette smoking plays a substantial role in the pathogenesis of numerous chronic diseases such as CV disease (CVD), cancer, lung disease and others. However, due to the existence of the so-called “smoking paradox”, the impact of this risk factor on CVD mortality is still not clear. Smoking cigarettes may increase risk of MetS or worsen it by numerous mechanisms. Furthermore, individuals who quit smoking tend to increase their body weight. The possibility of gaining weight can stop smokers from quitting and increases the risk of relapse, particularly in women. Herein, we review the cigarette smoking status (active/cessation) in relation to the MetS.
期刊介绍:
The Journal of Clinical Lipidology is published to support the diverse array of medical professionals who work to reduce the incidence of morbidity and mortality from dyslipidemia and associated disorders of lipid metabolism. The Journal''s readership encompasses a broad cross-section of the medical community, including cardiologists, endocrinologists, and primary care physicians, as well as those involved in the treatment of such disorders as diabetes, hypertension, and obesity. The Journal also addresses allied health professionals who treat the patient base described above, such as pharmacists, nurse practitioners and dietitians. Because the scope of clinical lipidology is broad, the topics addressed by the Journal are equally diverse. Typical articles explore lipidology as it is practiced in the treatment setting, recent developments in pharmacological research, reports of treatment and trials, case studies, the impact of lifestyle modification, and similar academic material of interest to the practitioner. While preference is given to material of immediate practical concern, the science that underpins lipidology is forwarded by expert contributors so that evidence-based approaches to reducing cardiovascular and coronary heart disease can be made immediately available to our readers. Sections of the Journal will address pioneering studies and the clinicians who conduct them, case studies, ethical standards and conduct, professional guidance such as ATP and NCEP, editorial commentary, letters from readers, National Lipid Association (NLA) news and upcoming event information, as well as abstracts from the NLA annual scientific sessions and the scientific forums held by its chapters, when appropriate.